The incidence of neoplasia in patients receiving tumour necrosis factor (TNF) antagonists appears to be less than 4%, with solid tumours being most frequent

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1160, 2007-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tumour necrosis factor antagonists

By Chantry D.  

Expert Opinion on Emerging Drugs, Vol. 4, Iss. 1, 1999-01 ,pp. : 5-13

Informa Healthcare

Access to resources Recommend Favorite

Leukaemic Transformation in Patients with Haematological Disease Receiving Tumour Necrosis Factor Inhibitors

By Ferrer-Marín Francisca   >   Vicente Vicente  

Clinical Drug Investigation, Vol. 32, Iss. 6, 2012-06 ,pp. : 423-426

Adis International

Access to resources Recommend Favorite

Safety of Tumour Necrosis Factor- Antagonists

By Khanna D.   McMahon M.   Furst D.E.  

Drug Safety, Vol. 27, Iss. 5, 2004-01 ,pp. : 307-324

Adis International

Access to resources Recommend Favorite

Inhibition of tumour necrosis factor-alpha (TNF-)

By Tu G.   Cau Q-n.   Zhou F.   Isreal Y.  

Expert Opinion on Therapeutic Targets, Vol. 2, Iss. 1, 1998-07 ,pp. : 23-25

Informa Healthcare

Access to resources Recommend Favorite

Tumour necrosis factor- antagonists and their therapeutic applications

By Lowe C.  

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 10, 1998-10 ,pp. : 1309-1322

Informa Healthcare

Access to resources Recommend Favorite